Todd P. Branning - Nov 3, 2022 Form 4 Insider Report for NeuBase Therapeutics, Inc. (NBSE)

Role: Chief Financial Officer
Signature: /s/ Todd P. Branning
Stock symbol: NBSE
Transactions as of: Nov 3, 2022
Transactions value $: $0
Form type: 4
Date filed: 11/4/2022, 05:00 PM
Previous filing: Mar 21, 2022
Next filing: Mar 17, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NBSE	Stock option (right to buy)	Award	$0	+200K		$0.00	200K	Nov 3, 2022	Common Stock	200K	$0.28	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	50% of the total shares shall vest on March 1, 2023, and the remaining shares shall vest on November 1, 2023, provided that vesting shall only occur on a scheduled vesting date if employment has not terminated prior to such vesting date, inclusive. Shares are subject to accelerated vesting in the event of a change of control of the Issuer, provided that employment has not terminated prior to such vesting date, inclusive.

Content

50% of the total shares shall vest on March 1, 2023, and the remaining shares shall vest on November 1, 2023, provided that vesting shall only occur on a scheduled vesting date if employment has not terminated prior to such vesting date, inclusive. Shares are subject to accelerated vesting in the event of a change of control of the Issuer, provided that employment has not terminated prior to such vesting date, inclusive.